Projects per year
Personal profile
Education
- 國立成功大學臨醫所博士
Research Interests
- 血液疾病
- 腫瘤治療
- 腸胃道腫瘤治療
- 頭頸癌治療
Experience
- 2020年08月 ~ 迄今 國立成功大學附設醫院 癌症中心 主任
- 2018年08月 ~ 迄今 國立成功大學 醫學系腫瘤醫學學科 教授且兼任主治醫師
- 2015年02月 ~ 2018年07月 國立成功大學 醫學系內科學科 副教授且兼任主治醫師
- 2008年08月 ~ 2015年01月 國立成功大學 醫學系內科學科 主治醫師且兼任助理教授
- 2005年12月 ~ 2007年11月 美國安德森癌症中心 分子細胞癌症所 研究員
- 2002年08月 ~ 2008年07月 國立成功大學附設醫院 內科部/血液腫瘤科 主治醫師
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 2 Zero Hunger -
SDG 3 Good Health and Well-being -
SDG 10 Reduced Inequalities
Fingerprint
Dive into the research topics where Chia-Jui Yen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 15 Finished
-
Investigating Novel Mechanisms and Therapeutic Targets in Igf2bp3-Pcsk9 Axis Essential for Orchestration of Hepatocellular Carcinoma Development
Yen, C.-J. (PI)
24-08-01 → 25-07-31
Project: Research project
-
-
Investigating Novel Mechanisms and Therapeutic Targets in Igf2bp3-Pcsk9 Axis Essential for Orchestration of Hepatocellular Carcinoma Development
Yen, C.-J. (PI)
22-08-01 → 23-07-31
Project: Research project
-
Establish Gastrointestinal Cancer Biomedical Databank and Develop Individual Precision Cancer Treatment( II )
Yen, C.-J. (PI)
22-05-01 → 23-04-30
Project: Research project
-
-
Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression
Wang, W. L., Yen, C. C., Yen, C. S., Huang, Y. H., Huang, H. Y., Chen, J. F., Liu, Y. Y., Wang, S. T., Liu, Y. T., Hung, M. C. & Yen, C. J., 2026 Mar 1, In: Cancer Letters. 640, 218255.Research output: Contribution to journal › Article › peer-review
2 Link opens in a new tab Citations (Scopus) -
First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial
Yang, Y., Yen, C. J., Pan, J., Wang, H., Qu, S., Chen, N., Chen, X., Sun, Y., He, X., Hu, C., Lin, L., Wu, Y., Yuan, S., Chen, C., Xu, X., Ma, X., Leaw, S., Zhang, L. & Fang, W., 2026, (Accepted/In press) In: JAMA Oncology.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Citations (Scopus) -
Inflammation-associated depression in cholangiocarcinoma: impacts of surgical resection and radiotherapy
Sung, T. H., Shen, Y. C., Yen, C. J., Shan, Y. S. & Chen, P. S., 2026 Dec, In: BioPsychoSocial Medicine. 20, 1, 3.Research output: Contribution to journal › Article › peer-review
Open Access -
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
Shitara, K., Bang, Y. J., Wyrwicz, L. S., Rha, S. Y., Oshima, T., Pietrantonio, F., Park, Y. K., Lonardi, S., Yañez, P., Yen, C. J., Metges, J. P., Garrido, M., Moehler, M., Pelles-Avraham, S., Yong, W. P., Spallanzani, A., Jensen, E., Krishnan, R., Shih, C. S. & Al-Batran, S. E., 2026 Mar, In: ESMO Open. 11, 3, 106090.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Citation (Scopus) -
Circulating tumor DNA methylation markers for the early diagnosis of hepatocellular carcinoma
Lu, C. Y., Tsai, K. F., Yen, C. J., Hsieh, C. J., Peng, P. J., Huang, S. C., Chuang, M. R. & Chu, C. J., 2025 Dec, In: Clinical and Experimental Medicine. 25, 1, 83.Research output: Contribution to journal › Article › peer-review
Open Access3 Link opens in a new tab Citations (Scopus)